Trials / Terminated
TerminatedNCT03896295
An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis
An Open-label Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Momenta Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the long-term safety and tolerability of M281 in participants with generalized myasthenia gravis (gMG)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | M281 | M281 injection administered as intravenous infusion |
Timeline
- Start date
- 2019-08-06
- Primary completion
- 2020-12-09
- Completion
- 2020-12-09
- First posted
- 2019-03-29
- Last updated
- 2023-06-27
- Results posted
- 2022-02-16
Locations
54 sites across 8 countries: United States, Belgium, Canada, Germany, Italy, Poland, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03896295. Inclusion in this directory is not an endorsement.